International Cannabis Reviews Asset Portfolio
February 22 2019 - 11:21AM
InvestorsHub Cannabis NewsWire
VANCOUVER, British Columbia,
Feb. 22, 2019 -- InvestorsHub NewsWire -- ICC
International Cannabis Corp. (CSE:WRLD.U)(8K51.F)(WLDCF)
("ICC" or “International
Cannabis”or the “Company”) is
pleased to provide the following updates pertaining to the
Company’s medical cannabis (“THC”) and cannabidiol (“CBD”) asset
portfolio.
Over the past three quarters,
International Cannabis has deployed an aggressive acquisition
strategy, amassing a robust portfolio of vertically integrated
cannabis assets and industry partnerships. Upon pending closing of
the Company’s proposed Letter of Intent (“LOI”) with Wayland Group,
the Company will boast the following operations, partnerships,
licenses and asset exposure:
- German medical Cannabis import license,
three-year supply contract to import 35,000 kg of medical cannabis,
165 hectares of CBD cultivation operations, annual production of
over 2,400 kilograms of CBD isolate, German indoor medical THC
cultivation licence application;
- 820,000 square foot Ebersbach facility
located just outside of Dresden, Germany:
- Replacement cost of 110 million euros;
- Of the many applicants to apply for German medical THC
cultivation licences, only two have a completed facility, and of
those that do, the largest is 14,000 square feet or 1.7 per cent
the size of the Ebersbach facility
- Danish medical THC cultivation and
manufacturing license:
- Stage A will include a 49,600 square foot cultivation unit, as
well as a production and processing structure. All structures
scheduled for construction have been designed to comply with EU-GMP
standards;
- 100 acre land package;
- Engagement of leading greenhouse engineering and manufacturing
firm, Azrom;
- No medical cannabis production cap or quotas;
- Access to skilled agricultural and manufacturing labour
force;
- Local plant breeding and genetics expertise; and
- Well-financed health care system
- Distribution or supply agreements with over
39,000 corporate and independent pharmacies, augmented by various
value-added services, including strategic procurement, warehousing,
product registrations and regulatory representations;
- 155 metric tonnes of extraction-ready hemp
inventories, resulting in near-immediate access to superior CBD
concentrates;
- Exclusive supply agreement for the delivery
of 400 metric tonnes of certified organic hemp from a licensed
Croatian producer;
- First European Guaranteed Issue Medical
Cannabis Coverage:
- First of its kind transformative coverage for cannabinoid
therapeutic treatment via the BuyWell Care platform;
- Online medical cannabis coverages utilizing a proprietary
pricing methodology;
- Over 500 million potential consumers;
- Over 1.6 million health care practitioners; and,
- Annual healthcare expenditures of $1.79 trillion in
2018.
- CBD Health and Wellness e-commerce
marketplace;
- Catalogue of 430 proprietary genetics,
seeds and strains;
- Polish hemp processing and extraction
license:
- Operations are currently producing CBD distillate, isolate,
bulk oils, and tinctures;
- Access to over 850 acres of premium hemp crops, estimated to
yield up to 6,800 tons of material for CBD extraction;
- Existing extraction and manufacturing facility; and,
- Existing sales agreements across various EU member
countries
- 60,000 square foot Swiss cannabis cultivation
facility, proprietary genetics portfolio available for export, THC
distillate import capabilities and pending material revenues from
Haxxon AG operations;
- Leading candidacy for one of seven medical
cannabis licences to be issued by the Italian government, as well
as an pending ownership interest in a joint venture to produce
cannabis products;
- Licenses for medical cannabis cultivation,
manufacturing, distribution, transport, research and import/export
in the Kingdom of Lesotho;
- Rich soils, ideal climate, skilled agricultural work force,
low-cost labour and access to key infrastructure;
- 300 days of sunshine annually;
- First African nation to legalize medical cannabis; and,
- Ideal climate for low-cost greenhouse cannabis
production
- Supply agreement to provide cannabis products
to over 2,800 independent and corporate pharmacies across South
Africa;
- Maltese licence to manufacture finished-dose
medical cannabis;
- Portuguese hemp cultivation and processing
license:
- Notable importer of EU licensed hemp seeds;
- Access to 400 acres of fertile agricultural land located in the
Castelo Branco region of Portugal; and,
- Progressing towards a full spectrum cannabis license;
- Colombian licences for THC/CBD production,
extraction and export, as well as pending access to a European
Union good-manufacturing-practice-certified API facility for
cannabis distillate processing;
- 90-per-cent working interest in a Greek
industrial hemp license and medical cannabis pre-approval support
letter:
- 16 acre land package situated within the Greek prefecture of
Imathia;
- Exclusive agreement with an existing
Macedonian licensed facility, permiting the cultivation,
manufacturing, extraction and export of medical cannabis:
- 3,000,000 square feet of cultivation space built under glass;
one of the largest impending European cannabis facilities;
- 30 hectare land parcel in Valandovo, Macedonia
- Licenses in Bulgaria for the production,
manufacturing and export of both hemp and medical cannabis;
- Leading candidacy for a United Kingdom-based
medical cannabis import licence;
- Leading candidacy for an Australian
late-stage medical cannabis;
- Leading candidacy for the first Argentine
federal medical cannabis licence and existing supply agreements for
CBD products;
International Cannabis is
uniquely positioned to capture significant market share, as the
European THC and CBD industries continue to mature. We have
tactically secured cornerstone assets Denmark and Germany-
jurisdictions armed with broad insurance coverage, affording the
Company the ability to realize substantially higher margins, while
insulating our operations from margin compression”.
The Company’s acquisition strategy,
including its proposed transaction with Wayland Group, further
reinforce the ICC’s corporate mandate of:
- Optimizing its upstream, downstream, and
distribution capabilities;
- Integrating operational best practices into
its medical plant production, extraction, active pharmaceutical
ingredient isolation and finished dose manufacturing
operations;
- Executing upon its first-mover advantage in
rapidly maturing jurisdictions;
- Providing a robust suite superior quality
products; and,
- Championing the European consumer’s THC/CBD
retail experience.
<p content="Mr. Beukman, continued: " our=""
extraction-ready="" hemp="" stockpiles,="" deep-seated=""
understanding="" of="" regional="" business="" practices="" and=""
vast="" pan-european="" distribution="" footprint="" safeguards=""
ability="" to="" maximize="" opportunities="" in="" europe's=""
emerging="" cbd="" thc="" markets.="" the="" company=""
continues="" place="" particular="" emphasis="" on="" furthering=""
its="" operations="" european="" latam="" regions="" will=""
look="" execute="" an="" assertive="" acquisition="" strategy=""
focused="" asia="" pacific="" theatre="" over="" upcoming=""
quarter"."="" data-reactid="46" type="text">Mr. Beukman,
continued: “Our extraction-ready hemp stockpiles, deep-seated
understanding of regional business practices and vast Pan-European
distribution footprint safeguards our ability to maximize
opportunities in Europe’s emerging CBD and THC markets. The Company
continues to place particular emphasis on furthering its operations
in the European and LATAM regions and will look to execute an
assertive acquisition strategy focused on Asia Pacific theatre over
the upcoming quarter”.
ABOUT INTERNATIONAL
CANNABIS
ICC International, through its
subsidiaries, has operating assets and is developing a world-class
platform for cultivation, extraction, formulation and distribution
across the globe in the United Kingdom, Denmark, Poland,
Switzerland, Germany, Macedonia, Bulgaria, Serbia, Croatia, Greece,
Italy, Portugal, Malta, Colombia, Argentina, Australia, South
Africa and Lesotho.
ON BEHALF OF THE ICC
INTERNATIONAL CANNABIS CORP BOARD OF DIRECTORS
Eugene Beukman
CEO, Director
+1 (604) 687-2038
info@intlcannabiscorp.com
Learn more about ICC by visiting our website at: https://intlcannabiscorp.com/
Stay up to date with everything happening at ICC by following or
liking us on:
Facebook - https://www.facebook.com/ICCWRLD/
Twitter - https://twitter.com/ICC_WRLD
LinkedIn - https://www.linkedin.com/company/icc-wrld/
THE CSE HAS NOT REVIEWED AND DOES NOT
ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS
RELEASE.
Notice Regarding Forward
Looking Information:
This news release contains certain
"forward-looking information" within the meaning of applicable
Canadian securities law. Forward-looking information is frequently
characterized by words such as "plan", "continue", "expect",
"project", "intend", "believe", "anticipate", "estimate", "may",
"will", "potential", "proposed" and other similar words, or
information that certain events or conditions "may" or "will"
occur. This information is only a prediction. Various assumptions
were used in drawing the conclusions or making the projections
contained in the forward-looking information throughout this news
release. Forward-looking information includes, but is not limited
to: political changes in Canada and internationally, future
legislative and regulatory developments involving cannabis in
Canada and internationally, the Company’s ability to secure
distribution channels in international jurisdictions, competition
and other risks affecting the Company in particular and the
cannabis industry generally.
The forward-looking information
contained in this release is expressly qualified by the foregoing
cautionary statements and is made as of the date of this release.
Except as may be required by applicable securities laws, the
Company does not undertake any obligation to publicly update or
revise any forward- looking information to reflect events or
circumstances after the date of this release or to reflect the
occurrence of unanticipated events, whether as a result of new
information, future events or results, or otherwise.